Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...

SEDA Experts LLC, a leading expert witness firm providing world-class financial expert witness services, announced today that ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

Pfizer has concluded a global licensing agreement with 3SBio, excluding China, which grants it exclusive rights for the 3SBio’s SSGJ-707.

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a final ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

A new study reveals that Pfizer’s COVID-19 vaccine may cause subtle but measurable changes in the eyes — specifically in the ...

A new study allegedly discovered that women using a specific form of birth control had a "significantly higher risk" of ...

Here are five high-yield dividend stocks that offer passive income and solid entry points that investors can buy and forget ...

Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...